Expression of integrin α3β1 and cyclooxygenase-2 (COX2) are positively correlated in human breast cancer

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Aggarwal, Anshu ^a   Al Rohil, Rami N ^b   Batra, Anupam ^b   Feustel, Paul J ^a   Jones, David M ^b   DiPersio, C Michael ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b ALBANY MEDICAL CENTER   (United States)

Author keywords

Breast cancer; COX2; Integrin 3 1; Invasive ductal carcinoma; PTGS2

Indexed keywords

CYCLOOXYGENASE 2; HORMONE RECEPTOR; VERY LATE ACTIVATION ANTIGEN 3; TUMOR MARKER;

ANGIOGENESIS; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CELL INVASION; CELL SURVIVAL; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; PARACRINE SIGNALING; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE MICROARRAY; TUMOR GROWTH; BREAST TUMOR; CANCER GRADING; FEMALE; GENETICS; METABOLISM; PATHOLOGY; TUMOR RECURRENCE;

BREAST NEOPLASMS; CYCLOOXYGENASE 2; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHA3BETA1; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL;

EID: 84902714404     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-459     Document Type: Article

References (54)

1. Brakebusch C, Bouvard D, Stanchi F, Sakai T, Fassler R. Integrins in invasive growth. J Clin Invest 2002, 109(8):999-1006.
2. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Canc 2010, 10(1):9-22.
3. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110(6):673-687.
4. Missan DS, DiPersio M. Integrin control of tumor invasion. Crit Rev Eukaryot Gene Expr 2012, 22(4):309-324.
5. Stipp CS. Laminin-binding integrins and their tetraspanin partners as potential antimetastatic targets. Expert Rev Mol Med 2010, 12:e3.
6. DiPersio CM, Hodivala-Dilke KM, Jaenisch R, Kreidberg JA, Hynes RO. Alpha3beta1 Integrin is required for normal development of the epidermal basement membrane. J Cell Biol 1997, 137(3):729-742.
7. Kreidberg JA. Functions of alpha3beta1 integrin. Curr Opin Cell Biol 2000, 12(5):548-553.
8. Kreidberg JA, Donovan MJ, Goldstein SL, Rennke H, Shepherd K, Jones RC, Jaenisch R. Alpha 3 beta 1 integrin has a crucial role in kidney and lung organogenesis. Development 1996, 122(11):3537-3547.
9. Raymond K, Cagnet S, Kreft M, Janssen H, Sonnenberg A, Glukhova MA. Control of mammary myoepithelial cell contractile function by alpha3beta1 integrin signalling. EMBO J 2011, 30(10):1896-1906.
10. Klinowska TC, Alexander CM, Georges-Labouesse E, Van der Neut R, Kreidberg JA, Jones CJ, Sonnenberg A, Streuli CH. Epithelial development and differentiation in the mammary gland is not dependent on alpha 3 or alpha 6 integrin subunits. Dev Biol 2001, 233(2):449-467.
11. Mitchell K, Svenson KB, Longmate WM, Gkirtzimanaki K, Sadej R, Wang X, Zhao J, Eliopoulos AG, Berditchevski F, DiPersio CM. Suppression of integrin alpha3beta1 in breast cancer cells reduces cyclooxygenase-2 gene expression and inhibits tumorigenesis, invasion, and cross-talk to endothelial cells. Canc Res 2010, 70(15):6359-6367.
12. Morini M, Mottolese M, Ferrari N, Ghiorzo F, Buglioni S, Mortarini R, Noonan DM, Natali PG, Albini A. The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. Int J Canc 2000, 87(3):336-342.
13. Subbaram S, DiPersio CM. Integrin alpha3beta1 as a breast cancer target. Expert Opin Ther Targets 2011, 15(10):1197-1210.
14. Giannelli G, Fransvea E, Marinosci F, Bergamini C, Colucci S, Schiraldi O, Antonaci S. Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin. Am J Pathol 2002, 161(1):183-193.
15. Zhou B, Gibson-Corley KN, Herndon ME, Sun Y, Gustafson-Wagner E, Teoh-Fitzgerald M, Domann FE, Henry MD, Stipp CS. Integrin alpha3beta1 can function to promote spontaneous metastasis and lung colonization of invasive breast carcinoma. Mol Canc Res 2014, 12(1):143-154.
16. Chia J, Kusuma N, Anderson R, Parker B, Bidwell B, Zamurs L, Nice E, Pouliot N. Evidence for a role of tumor-derived laminin-511 in the metastatic progression of breast cancer. Am J Pathol 2007, 170(6):2135-2148.
17. Kim BG, Gao MQ, Choi YP, Kang S, Park HR, Kang KS, Cho NH. Invasive breast cancer induces laminin-332 upregulation and integrin beta4 neoexpression in myofibroblasts to confer an anoikis-resistant phenotype during tissue remodeling. Breast Canc Res 2012, 14(3):R88.
18. Kwon SY, Chae SW, Wilczynski SP, Carpenter AA, Philip M. Laminin 332 expression in breast carcinoma. Appl Immunohistochemistry Mol Morphol: AIMM/Offic Publ Soc Appl Immunohistochemistry 2012, 20(2):159-164.
19. Marinkovich MP. Tumour microenvironment: Laminin 332 in squamous-cell carcinoma. Nat Rev Canc 2007, 7(5):370-380.
20. Tsuruta D, Kobayashi H, Imanishi H, Sugawara K, Ishii M, Jones JC. Laminin-332-integrin interaction: a target for cancer therapy?. Curr Med Chem 2008, 15(20):1968-1975.
21. Howe LR. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Canc Res 2007, 9(4):210.
22. Howe LR, Subbaramaiah K, Brown AM, Dannenberg AJ. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Canc 2001, 8(2):97-114.
23. Singh-Ranger G, Salhab M, Mokbel K. The role of cyclooxygenase-2 in breast cancer: review. Breast Canc Res Treat 2008, 109(2):189-198.
24. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006, 332(7553):1302-1308.
25. Kwan ML, Habel LA, Slattery ML, Caan B. NSAIDs and breast cancer recurrence in a prospective cohort study. Canc Causes Contr 2007, 18(6):613-620.
26. van Nes JG, de Kruijf EM, Faratian D, van de Velde CJ, Putter H, Falconer C, Smit VT, Kay C, van de Vijver MJ, Kuppen PJ, Bartlett JM. COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients. Breast Canc Res Treat 2011, 125(3):671-685.
27. Ashok V, Dash C, Rohan TE, Sprafka JM, Terry PD. Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. Breast 2011, 20(1):66-70.
28. Baron JA, Sandler RS, Bresalier RS, Lanas A, Morton DG, Riddell R, Iverson ER, Demets DL. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 2008, 372(9651):1756-1764.
29. Cannon CP, Cannon PJ. Physiology. COX-2 inhibitors and cardiovascular risk. Science 2012, 336(6087):1386-1387.
30. Atukorala I, Hunter DJ. Valdecoxib : the rise and fall of a COX-2 inhibitor. Expert Opin Pharmacother 2013, 14(8):1077-1086.
31. Marnett LJ. The COXIB experience: a look in the rearview mirror. Annu Rev Pharmacol Toxicol 2009, 49:265-290.
32. Aggarwal A, Hunter WJ, Aggarwal H, Silva ED, Davey MS, Murphy RF, Agrawal DK. Expression of leukemia/lymphoma-related factor (LRF/POKEMON) in human breast carcinoma and other cancers. Exp Mol Pathol 2010, 89(2):140-148.
33. DiPersio CM, Shah S, Hynes RO. Alpha 3A beta 1 integrin localizes to focal contacts in response to diverse extracellular matrix proteins. J Cell Sci 1995, 108(Pt 6):2321-2336.
34. DiPersio CM, van der Neut R, Georges-Labouesse E, Kreidberg JA, Sonnenberg A, Hynes RO. Alpha3beta1 and alpha6beta4 integrin receptors for laminin-5 are not essential for epidermal morphogenesis and homeostasis during skin development. J Cell Sci 2000, 113(Pt 17):3051-3062.
35. Mitchell K, Szekeres C, Milano V, Svenson KB, Nilsen-Hamilton M, Kreidberg JA, DiPersio CM. Alpha3beta1 integrin in epidermis promotes wound angiogenesis and keratinocyte-to-endothelial-cell crosstalk through the induction of MRP3. J Cell Sci 2009, 122(Pt 11):1778-1787.
36. Hashida H, Takabayashi A, Tokuhara T, Taki T, Kondo K, Kohno N, Yamaoka Y, Miyake M. Integrin alpha3 expression as a prognostic factor in colon cancer: association with MRP-1/CD9 and KAI1/CD82. Int J Canc 2002, 97(4):518-525.
37. Shirakihara T, Kawasaki T, Fukagawa A, Semba K, Sakai R, Miyazono K, Miyazawa K, Saitoh M. Identification of integrin alpha3 as a molecular marker of cells undergoing epithelial-mesenchymal transition and of cancer cells with aggressive phenotypes. Canc Sci 2013, 104(9):1189-1197.
38. Patriarca C, Ivanyi D, Fles D, de Melker A, van Doornewaard G, Oomen L, Alfano RM, Coggi G, Sonnenberg A. Distribution of extracellular and cytoplasmic domains of the alpha 3 and alpha 6 integrin subunits in solid tumors. Int J Canc 1995, 63(2):182-189.
39. Chow LW, Loo WT, Toi M. Current directions for COX-2 inhibition in breast cancer. Biomed Pharmacother 2005, 59(Suppl 2):S281-S284.
40. Goodman SL, Picard M. Integrins as therapeutic targets. Trends Pharmacol Sci 2012, 33(7):405-412.
41. Stupp R, Ruegg C. Integrin inhibitors reaching the clinic. J Clin Oncol 2007, 25(13):1637-1638.
42. Ramirez NE, Zhang Z, Madamanchi A, Boyd KL, O'Rear LD, Nashabi A, Li Z, Dupont WD, Zijlstra A, Zutter MM. The alpha(2)beta(1) integrin is a metastasis suppressor in mouse models and human cancer. J Clin Invest 2011, 121(1):226-237.
43. Wang H, Fu W, Im JH, Zhou Z, Santoro SA, Iyer V, DiPersio CM, Yu QC, Quaranta V, Al-Mehdi A, Muschel RJ. Tumor cell alpha3beta1 integrin and vascular laminin-5 mediate pulmonary arrest and metastasis. J Cell Biol 2004, 164(6):935-941.
44. Yang XH, Richardson AL, Torres-Arzayus MI, Zhou P, Sharma C, Kazarov AR, Andzelm MM, Strominger JL, Brown M, Hemler ME. CD151 accelerates breast cancer by regulating alpha 6 integrin function, signaling, and molecular organization. Canc Res 2008, 68(9):3204-3213.
45. Subbaram S, Lyons SP, Svenson KB, Hammond SL, McCabe LG, Chittur SV, DiPersio CM. Integrin alpha3beta1 controls mRNA splicing that determines cyclooxygenase (Cox-2) mRNA stability in breast cancer cells. J Cell Sci 2014, 127(Pt 6):1179-1189.
46. DiPersio CM, Shao M, Di Costanzo L, Kreidberg JA, Hynes RO. Mouse keratinocytes immortalized with large T antigen acquire alpha3beta1 integrin-dependent secretion of MMP-9/gelatinase B. J Cell Sci 2000, 113(Pt 16):2909-2921.
47. Kamoshida G, Matsuda A, Katabami K, Kato T, Mizuno H, Sekine W, Oku T, Itoh S, Tsuiji M, Hattori Y, Maitani Y, Tsuji T. Involvement of transcription factor Ets-1 in the expression of the alpha3 integrin subunit gene. FEBS J 2012, 279(24):4535-4546.
48. Cagnet S, Faraldo MM, Kreft M, Sonnenberg A, Raymond K, Glukhova MA. Signaling events mediated by alpha3beta1 integrin are essential for mammary tumorigenesis. Oncogene advance online publication, 2013 Sep 30; doi: 10.1038/onc.2013.391.
49. Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Holm R, Giercksky KE, Nesland JM. Expression of cyclooxygenase-2 in invasive breast carcinomas and its prognostic impact. Histol Histopathol 2012, 27(10):1315-1325.
50. Glynn SA, Prueitt RL, Ridnour LA, Boersma BJ, Dorsey TM, Wink DA, Goodman JE, Yfantis HG, Lee DH, Ambs S. COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer. BMC Canc 2010, 10:626.
51. Adachi M, Taki T, Huang C, Higashiyama M, Doi O, Tsuji T, Miyake M. Reduced integrin alpha3 expression as a factor of poor prognosis of patients with adenocarcinoma of the lung. J Clin Oncol 1998, 16(3):1060-1067.
52. Suzuki N, Higashiguchi A, Hasegawa Y, Matsumoto H, Oie S, Orikawa K, Ezawa S, Susumu N, Miyashita K, Aoki D. Loss of integrin alpha3 expression associated with acquisition of invasive potential by ovarian clear cell adenocarcinoma cells. Hum Cell 2005, 18(3):147-155.
53. Varzavand A, Drake JM, Svensson RU, Herndon ME, Zhou B, Henry MD, Stipp CS. Integrin alpha3beta1 regulates tumor cell responses to stromal cells and can function to suppress prostate cancer metastatic colonization. Clin Exp Metastasis 2013, 30(4):541-552.
54. Sachs N, Secades P, van Hulst L, Kreft M, Song JY, Sonnenberg A. Loss of integrin alpha3 prevents skin tumor formation by promoting epidermal turnover and depletion of slow-cycling cells. Proc Natl Acad Sci U S A 2012, 109(52):21468-21473.